FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286943473> ?p ?o ?g. }

• W2286943473 endingPage "454" @default.
• W2286943473 startingPage "447" @default.
• W2286943473 abstract "The aim of this preliminary study is to evaluate clinical and imaging response in twenty patients with early Rheumatoid Arthritits (eRA) treated with Etanercept (Etn) + Methotrexate (Mtx) and to investigate whether clinical and MRI remission may be maintained after biological therapy interruption. Assessment included: radiography, Visser score and anti-CCP antibodies at baseline; disease activity score in 44 joints (DAS 44 ), rheumatoid factor (RF), Magnetic Resonance Imaging (MRI) of hands and wrists at baseline (T0), 12 (T1), and 24 months (T2). MRI was scored for synovitis, bone oedema and erosions (OMERACT study); patients who reached clinical and imaging remission at T1 were considered eligible for interrupting Etn. At T1 8/20 (40%) patients showed a total remission [DAS 44 from 5 (T0) to 1.4 (T1); p<0.02], whereas the other 12/20 (60%) showed an improvement, without complete remission [DAS44 from 4.8 (T0) to 2.8 (T1); p<0.05]. Etn was therefore interrupted in the first group of patients (group A), whereas it was continued in the other group (group B). At T2, group A maintained clinical remission and group B showed further not significant DAS 44 reduction from T1. At T1, a significant reduction in synovitis, bone oedema and total score (p<0.01) was observed both in group A and in group B. At T2, group A showed an increase in all the MRI scores that was significant for the synovitis and total score, whereas group B exhibited a further not significant reduction. This preliminary study reports an excellent clinical and imaging response in eRA patients treated with Etn with total remission in 40% of them after a 1-year therapy period. However, it indicates that joint damage may progress, despite a sustained clinical remission, after Etn suspension" @default.
• W2286943473 created "2016-06-24" @default.
• W2286943473 creator A5000691915 @default.
• W2286943473 creator A5003861711 @default.
• W2286943473 creator A5016933710 @default.
• W2286943473 creator A5017921726 @default.
• W2286943473 creator A5026977952 @default.
• W2286943473 creator A5028968989 @default.
• W2286943473 creator A5035571932 @default.
• W2286943473 creator A5048907156 @default.
• W2286943473 creator A5080570898 @default.
• W2286943473 creator A5086236783 @default.
• W2286943473 date "2009-04-01" @default.
• W2286943473 modified "2023-09-26" @default.
• W2286943473 title "Imaging Progression despite Clinical Remission in Early Rheumatoid Arthritis Patients after Etanercept Interruption" @default.
• W2286943473 cites W1983134858 @default.
• W2286943473 cites W2000905503 @default.
• W2286943473 cites W2005429018 @default.
• W2286943473 cites W2043343045 @default.
• W2286943473 cites W2066357843 @default.
• W2286943473 cites W2072489496 @default.
• W2286943473 cites W2091732273 @default.
• W2286943473 cites W2099885994 @default.
• W2286943473 cites W2110324649 @default.
• W2286943473 cites W2130766662 @default.
• W2286943473 cites W2148930631 @default.
• W2286943473 cites W2150301963 @default.
• W2286943473 cites W2152348310 @default.
• W2286943473 cites W2168735834 @default.
• W2286943473 cites W4242812997 @default.
• W2286943473 doi "https://doi.org/10.1177/039463200902200221" @default.
• W2286943473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19505397" @default.
• W2286943473 hasPublicationYear "2009" @default.
• W2286943473 type Work @default.
• W2286943473 sameAs 2286943473 @default.
• W2286943473 citedByCount "12" @default.
• W2286943473 countsByYear W22869434732012 @default.
• W2286943473 countsByYear W22869434732013 @default.
• W2286943473 countsByYear W22869434732014 @default.
• W2286943473 countsByYear W22869434732017 @default.
• W2286943473 countsByYear W22869434732018 @default.
• W2286943473 countsByYear W22869434732019 @default.
• W2286943473 countsByYear W22869434732022 @default.
• W2286943473 crossrefType "journal-article" @default.
• W2286943473 hasAuthorship W2286943473A5000691915 @default.
• W2286943473 hasAuthorship W2286943473A5003861711 @default.
• W2286943473 hasAuthorship W2286943473A5016933710 @default.
• W2286943473 hasAuthorship W2286943473A5017921726 @default.
• W2286943473 hasAuthorship W2286943473A5026977952 @default.
• W2286943473 hasAuthorship W2286943473A5028968989 @default.
• W2286943473 hasAuthorship W2286943473A5035571932 @default.
• W2286943473 hasAuthorship W2286943473A5048907156 @default.
• W2286943473 hasAuthorship W2286943473A5080570898 @default.
• W2286943473 hasAuthorship W2286943473A5086236783 @default.
• W2286943473 hasConcept C126322002 @default.
• W2286943473 hasConcept C126838900 @default.
• W2286943473 hasConcept C141071460 @default.
• W2286943473 hasConcept C143409427 @default.
• W2286943473 hasConcept C2776232647 @default.
• W2286943473 hasConcept C2777077863 @default.
• W2286943473 hasConcept C2777226972 @default.
• W2286943473 hasConcept C2777575956 @default.
• W2286943473 hasConcept C2777785397 @default.
• W2286943473 hasConcept C2779244835 @default.
• W2286943473 hasConcept C2781059491 @default.
• W2286943473 hasConcept C2989005 @default.
• W2286943473 hasConcept C71924100 @default.
• W2286943473 hasConcept C90924648 @default.
• W2286943473 hasConceptScore W2286943473C126322002 @default.
• W2286943473 hasConceptScore W2286943473C126838900 @default.
• W2286943473 hasConceptScore W2286943473C141071460 @default.
• W2286943473 hasConceptScore W2286943473C143409427 @default.
• W2286943473 hasConceptScore W2286943473C2776232647 @default.
• W2286943473 hasConceptScore W2286943473C2777077863 @default.
• W2286943473 hasConceptScore W2286943473C2777226972 @default.
• W2286943473 hasConceptScore W2286943473C2777575956 @default.
• W2286943473 hasConceptScore W2286943473C2777785397 @default.
• W2286943473 hasConceptScore W2286943473C2779244835 @default.
• W2286943473 hasConceptScore W2286943473C2781059491 @default.
• W2286943473 hasConceptScore W2286943473C2989005 @default.
• W2286943473 hasConceptScore W2286943473C71924100 @default.
• W2286943473 hasConceptScore W2286943473C90924648 @default.
• W2286943473 hasIssue "2" @default.
• W2286943473 hasLocation W22869434731 @default.
• W2286943473 hasLocation W22869434732 @default.
• W2286943473 hasOpenAccess W2286943473 @default.
• W2286943473 hasPrimaryLocation W22869434731 @default.
• W2286943473 hasRelatedWork W1995727207 @default.
• W2286943473 hasRelatedWork W2090686119 @default.
• W2286943473 hasRelatedWork W2104646232 @default.
• W2286943473 hasRelatedWork W2314052274 @default.
• W2286943473 hasRelatedWork W2352829214 @default.
• W2286943473 hasRelatedWork W2583372832 @default.
• W2286943473 hasRelatedWork W2946515647 @default.
• W2286943473 hasRelatedWork W3031634535 @default.
• W2286943473 hasRelatedWork W3045308555 @default.
• W2286943473 hasRelatedWork W2314697596 @default.
• W2286943473 hasVolume "22" @default.

• next